Charles A. Simonton, MD, FACC, FSCAI

EVP Chief Medical Officer
Abiomed Inc
Charlotte, North Carolina, United States

Charles Simonton, MD joined Abiomed in June 2020 as Vice President and Chief Medical Officer. He is renowned for his leadership in product development and large-scale clinical trials. From 2008-2019 he was at Abbott Vascular where he served as chief medical officer and divisional vice president of global medical affairs. He led the programs that resulted in the FDA's approval of carotid stents, MitraClip™ and Absorb BVS, in addition to the EXCEL and COAPT trials. Prior to Abbott, Dr. Simonton spent 25 years as an interventional cardiologist working with complex cardiac and vascular patients at Duke University Medical Center and the Sanger Clinic in Charlotte NC. He received his medical degree from Harvard Medical School and did his internship, residency and chief residency in the Department of Internal Medicine at the University of California and his cardiology fellowship at Duke University.

Presentation(s):

• Panel Discussion

  Saturday, February 25, 2023
  10:30 AM – 10:50 AM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Shock-ARC (SHARC) Working Group | Panel Disucssion

  Saturday, February 25, 2023
  1:20 PM – 1:40 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Panel Discussion

  Saturday, February 25, 2023
  4:10 PM – 5:20 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• CARDIOTUBE INTERIVEW: Update on Recover and Protect 4 studies

  Sunday, February 26, 2023
  8:30 AM – 8:40 AM ET

  Disclosure information not submitted.

• Panel Discussion | Forthcoming Pathways in Interventional Cardiology

  Monday, February 27, 2023
  3:30 PM – 3:45 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Breaking the "Small Bore Barrier" in pMCS for High Risk PCI: Early Experience with the IMPELLA ECP Device

  Tuesday, February 28, 2023
  8:00 AM – 8:12 AM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Panel Discussion | Challenges Designing Clinical Trials for Heart Failures Using the MCP Devices

  Tuesday, February 28, 2023
  8:59 AM – 9:30 AM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Challenges With Cardiogenic Shock Studies in the US

  Tuesday, February 28, 2023
  11:58 AM – 12:06 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Industry Perspective

  Tuesday, February 28, 2023
  12:22 PM – 12:30 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Panel Discussion: How to Optimize Clinical Trials for Devices for Heart Failure in the Era of the Pandemic and New Medical Therapeutics

  Tuesday, February 28, 2023
  12:30 PM – 1:00 PM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• The US EFS Program: Industry Perspective and Case Example

  Tuesday, February 28, 2023
  8:24 AM – 8:32 AM ET

  Disclosure(s): Abiomed: Employee (Ongoing)

• Panel Discussion: Innovative Technology Headwinds and Tailwinds

  Tuesday, February 28, 2023
  8:48 AM – 9:15 AM ET

  Disclosure(s): Abiomed: Employee (Ongoing)